← back to search

Caroline Happold

University Hospital of Zurich ·
Area of research
Genetics · Immunology
Research interest
Research interests include Glioma Diagnosis and Treatment, interferon and immune responses, Brain Metastases and Treatment, and MicroRNA in disease regulation.
h-index
20
citations
1,795
works
66
NIH funding
primary concept
email

Recent publications

Impact of predictive impact of MGMT promoter methylation in malignant astrocytomas depends on the methylation subgroup.
Journal of Clinical Oncology 2019cited by 1position: middledoi
Do statins, ACE inhibitors or sartans improve outcome in primary glioblastoma?
Journal of Neuro-Oncology 2018cited by 38position: firstdoi
Clinical and molecular features associated with long-term survival of elderly patients with glioblastoma.
Journal of Clinical Oncology 2017cited by 1position: middledoi
Long-term analysis of the NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with PCV or temozolomide
Neuro-Oncology 2016cited by 227position: middledoi
Does Valproic Acid or Levetiracetam Improve Survival in Glioblastoma? A Pooled Analysis of Prospective Clinical Trials in Newly Diagnosed Glioblastoma
Journal of Clinical Oncology 2016cited by 210position: firstdoi
MicroRNA-138 promotes acquired alkylator resistance in glioblastoma by targeting the Bcl-2-interacting mediator BIM
Oncotarget 2016cited by 63position: lastdoi
ACTR-18. MOLECULAR GENETIC, HOST-DERIVED AND CLINICAL DETERMINANTS OF LONG-TERM SURVIVAL IN GLIOBLASTOMA: AN UPDATE FROM THE BRAIN TUMOR FUNDERS’ COLLABORATIVE CONSORTIUM
Neuro-Oncology 2016cited by 2position: firstdoi
Reply to F. Felix et al and M.F. Fay et al
Journal of Clinical Oncology 2016cited by 1position: firstdoi
Interferon-β Modulates the Innate Immune Response against Glioblastoma Initiating Cells
PLoS ONE 2015cited by 11position: middledoi
ATNT-10DOES VALPROIC ACID IMPROVE SURVIVAL IN GLIOBLASTOMA? A META-ANALYSIS OF RANDOMIZED TRIALS IN NEWLY DIAGNOSED GLIOBLASTOMA
Neuro-Oncology 2015cited by 3position: firstdoi
Interferon-β Induces Loss of Spherogenicity and Overcomes Therapy Resistance of Glioblastoma Stem Cells
Molecular Cancer Therapeutics 2014cited by 47position: firstdoi
Malignant astrocytomas of elderly patients lack favorable molecular markers: an analysis of the NOA-08 study collective
Neuro-Oncology 2013cited by 94position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Michael Weller · Center for Neurosciences12 papers (2013–2019)Patrick Roth · University Hospital of Zurich8 papers (2014–2016)Guido Reifenberger · University of Toronto7 papers (2013–2019)Wolfgang Wick · Heidelberger Institut für Radioonkologie6 papers (2013–2019)Thierry Gorlia · Aix-Marseille Université4 papers (2015–2018)Roger Stupp · Northwestern University4 papers (2015–2018)David A. Reardon · Massachusetts Institute of Technology4 papers (2015–2018)Burt Nabors · Neurology, Inc4 papers (2015–2018)Stephanie L. Pugh · NRG Oncology3 papers (2015–2016)Minesh P. Mehta · Carbon Engineering (Canada)3 papers (2015–2016)Monika E. Hegi · University Hospital of Lausanne3 papers (2015–2016)Ana‐Maria Florea · Heinrich Heine University Düsseldorf3 papers (2014–2016)Andreas von Deimling · Stiftung Schleswig-Holsteinische Landesmuseen3 papers (2016–2019)Timothy F. Cloughesy · UCLA Medical Center3 papers (2015–2016)Mark R. Gilbert · BC Centre for Disease Control3 papers (2015–2016)Michael Platten · German Cancer Research Center3 papers (2013–2019)Olivier Chinot · Peuplements végétaux et bioagresseurs en milieu tropical3 papers (2015–2016)James Perry · University of Arkansas for Medical Sciences3 papers (2015–2016)Michael Bamberg · Universitätsklinikum Tübingen2 papers (2016–2019)Katrin Lamszus · Universität Hamburg2 papers (2014–2015)